Free Trial
NASDAQ:VTVT

vTv Therapeutics (VTVT) Stock Price, News & Analysis

vTv Therapeutics logo
$13.53 -1.53 (-10.16%)
Closing price 07/3/2025 02:15 PM Eastern
Extended Trading
$14.07 +0.54 (+3.98%)
As of 07/3/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About vTv Therapeutics Stock (NASDAQ:VTVT)

Key Stats

Today's Range
$15.07
$15.07
50-Day Range
$13.53
$23.17
52-Week Range
$12.12
$26.99
Volume
2,082 shs
Average Volume
23,162 shs
Market Capitalization
$43.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.50
Consensus Rating
Buy

Company Overview

vTv Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

VTVT MarketRank™: 

vTv Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 644th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    vTv Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    vTv Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about vTv Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of vTv Therapeutics is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of vTv Therapeutics is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    vTv Therapeutics has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about vTv Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.21% of the float of vTv Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    vTv Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in vTv Therapeutics has recently decreased by 3.74%, indicating that investor sentiment is improving.
  • Dividend Yield

    vTv Therapeutics does not currently pay a dividend.

  • Dividend Growth

    vTv Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.21% of the float of vTv Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    vTv Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in vTv Therapeutics has recently decreased by 3.74%, indicating that investor sentiment is improving.
  • News Sentiment

    vTv Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for vTv Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, vTv Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.20% of the stock of vTv Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 17.51% of the stock of vTv Therapeutics is held by institutions.

  • Read more about vTv Therapeutics' insider trading history.
Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTVT Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

VTVT Stock Analysis - Frequently Asked Questions

vTv Therapeutics' stock was trading at $13.81 at the beginning of 2025. Since then, VTVT stock has decreased by 2.0% and is now trading at $13.53.

vTv Therapeutics Inc. (NASDAQ:VTVT) issued its earnings results on Thursday, May, 15th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by $0.04.

vTv Therapeutics shares reverse split on the morning of Tuesday, November 21st 2023.The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

vTv Therapeutics (VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that vTv Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), NIO (NIO), VBI Vaccines (VBIV), Vaxart (VXRT) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/15/2025
Today
7/05/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VTVT
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.50
High Stock Price Target
$36.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+162.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.46 million
Pretax Margin
-134,723.52%

Debt

Sales & Book Value

Annual Sales
$1.02 million
Price / Cash Flow
N/A
Book Value
$4.48 per share
Price / Book
3.02

Miscellaneous

Free Float
3,061,000
Market Cap
$43.16 million
Optionable
Not Optionable
Beta
0.58

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:VTVT) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners